Deutsche Bank Ups Illumina Stock to Buy | GenomeWeb
NEW YORK (GenomeWeb News) — Investment bank Deutsche Bank today upgraded Illumina’s stock to ‘buy’ from ‘hold’ after the company last week reported strong fourth-0quarter revenues but warned of high costs this year.
 
As GenomeWeb News reported last week, Illumina said total revenues for the three months ended Dec. 31, 2006, jumped 163 percent as R&D spending rose 17 percent and profit soared.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A Karmagenes researcher has lost his position after reportedly admitting to data fabrication, according to Retraction Watch.

Two neuroscientists write in Nature News that solving the "reproducibility crisis" in science may require changing the requirements for publication.

In Nature this week: genomic analysis of prehistoric New Mexicans, a nanopore method for mapping DNA methylation, and more.

A new study finds that adding missing good bacteria to the skin microbiome of atopic dermatitis patients decreases Staphylococcus aureus colonization.